Nuclide Therapeutics builds leaner radiopharmaceuticals
At a glance Publicly launched: 2024 Headquarters: London Technology: Small-molecule therapeutics and diagnostics containing radioactive halogen isotopes…
Nuclide Therapeutics secures over $6 million for drugs against treatment-resistance cancers
Nuclide Therapeutics, a King’s College London spinout developing radioactive drugs to target therapy-resistant cancers, has closed a…